drugset / Trial / NCT04687878

The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients

NCT04687878

Phase 2 Completed 28 enrolled dr.dargahi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effect of intranasal insulin on motor and non-motor symptoms of patients with Parkinson's disease over a 12-week period.

Timeline

Start
2020-01-01
Primary completion
2022-06-20
Completion
2023-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 20 iu Intranasal

Indications